Lentigen Licenses Lentiviral IP from Cambridge | GenomeWeb

Lentigen Licenses Lentiviral IP from Cambridge

Apr 03, 2008

NEW YORK (GenomeWeb News) – Lentigen has licensed an HIV-related lentiviral vector technology patent held by the University of Cambridge, the company said today.

Baltimore-based Lentigen signed an exclusive agreement with Cambridge Enterprise, the technology licensing arm of the University of Cambridge, for technology that was developed by Andrew Lever.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.